Cipla flagged up supply-related strains for its lead peptide asset, lanreotide injection, in the US, with the impact seen spilling into the next quarter, even as the company readies a number of growth levers including a potential entry in the GLP-1 space in India (see side box).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?